株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

疣贅:パイプライン製品の分析

Warts - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 200501
出版日 ページ情報 英文 105 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.67円で換算しております。
Back to Top
疣贅:パイプライン製品の分析 Warts - Pipeline Review, H2 2019
出版日: 2019年09月23日 ページ情報: 英文 105 Pages
概要

疣贅は、ヒトパピローマウイルス(HPV)により、小さく痛みの無い局所的な皮膚腫瘍を指します。疣贅には様々な種類が存在し、手の上に現れる一般的な「いぼ」や、顔面上・前額部の平らな疣贅、性器上に生じる陰部疣贅(コンジローマ)、足の裏にできる足底疣贅、手爪・足爪の下や周囲に生じる爪下・爪周囲いぼなどが挙げられます。主な症状には、傷口近辺の皮膚が極端に黒く/白くなることや、前額部・頬・腕・脚にできる多数の小さく滑らかで平らな傷口、手爪・足爪の下や周囲に生じる凹凸状の腫瘍、足の裏にある楕円状の傷口などがあります。形状はどれも平坦か少し盛り上がっていて、圧迫感を伴い、小さく硬い傷口か塊となっています。持続性の疣贅を除去する際には、ポドフィリンやサルチル酸といった医薬品が処方されますが、外科手術や冷却(冷凍療法)、燃焼(電気焼灼法)といった手段もとられます。

当レポートでは、世界各国での疣贅(いぼ)治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

  • 分析範囲

疣贅の概要

治療薬の開発

  • 疣贅向けパイプライン製品:概要
  • 疣贅向けパイプライン製品:比較分析

各企業で開発中の疣贅治療薬

パイプライン製品の概略

  • 治験段階の製品
  • 初期段階の製品

疣贅治療薬:開発中の製品の一覧(企業別)

疣贅治療薬の開発に従事している企業

疣贅病:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 機能メカニズム別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

疣贅治療薬:最新の薬剤プロファイル

疣贅治療薬:休止状態のプロジェクト

疣贅治療薬:開発が中止された製品

疣贅関連製品の開発のマイルストーン

付録

図表

List of Tables

  • Number of Products under Development for Warts, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Warts - Pipeline by Aclaris Therapeutics Inc, H2 2019
  • Warts - Pipeline by Cutanea Life Sciences Inc, H2 2019
  • Warts - Pipeline by Cytovation AS, H2 2019
  • Warts - Pipeline by G&E Corp, H2 2019
  • Warts - Pipeline by Genetic Immunity Inc, H2 2019
  • Warts - Pipeline by Laboratories Ojer Pharma SL, H2 2019
  • Warts - Pipeline by Leo Pharma AS, H2 2019
  • Warts - Pipeline by Maruho Co Ltd, H2 2019
  • Warts - Pipeline by Nielsen Biosciences Inc, H2 2019
  • Warts - Pipeline by Novan Inc, H2 2019
  • Warts - Pipeline by Pfizer Inc, H2 2019
  • Warts - Pipeline by Phio Pharmaceuticals Corp, H2 2019
  • Warts - Pipeline by Tamir Biotechnology Inc, H2 2019
  • Warts - Pipeline by Verrica Pharmaceuticals Inc, H2 2019
  • Warts - Dormant Projects, H2 2019
  • Warts - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Warts - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Warts, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
目次
Product Code: GMDHC11404IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Warts - Pipeline Review, H2 2019, provides an overview of the Warts (Infectious Disease) pipeline landscape.

Warts are skin growth that is caused by virus called human papillomavirus (HPV). HPV infects the top layer of skin, usually entering the body in an area of broken skin. The virus causes the top layer of skin to grow rapidly, forming a wart. Symptoms include pain and rough skin. Predisposing factors include age and people with weakened immune systems, such as those with HIV/AIDS or people who had organ transplants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Warts - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Warts (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Warts (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Warts and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 12, 5, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 2 and 2 molecules, respectively.

Warts (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Warts (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Warts (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Warts (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Warts (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Warts (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Warts (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Warts (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
    • Warts - Overview
    • Warts - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
  • Products under Development by Universities/Institutes
    • Warts - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Warts - Companies Involved in Therapeutics Development
    • Aclaris Therapeutics Inc
    • Cutanea Life Sciences Inc
    • Cytovation AS
    • G&E Corp
    • Genetic Immunity Inc
    • Laboratories Ojer Pharma SL
    • Leo Pharma AS
    • Maruho Co Ltd
    • Nielsen Biosciences Inc
    • Novan Inc
    • Pfizer Inc
    • Phio Pharmaceuticals Corp
    • Tamir Biotechnology Inc
    • Verrica Pharmaceuticals Inc
  • Warts - Drug Profiles
    • (digoxin + furosemide) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Albicin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AS-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Condyloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Human Papillomavirus Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CyPep-1 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FIT-039 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • furosemide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus (9 valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus (9 valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotypes 6, 11] (bivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotypes 6, 11] (bivalent, virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HupaDerm - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrogen peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ingenol mebutate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • interferon alfa-2b - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omiganan pentahydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pefcalcitol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PP-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ranpirnase - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RKP-00156 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Samcyprone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SB-206 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Warts - Dormant Projects
  • Warts - Discontinued Products
  • Warts - Product Development Milestones
    • Featured News & Press Releases
      • Jul 24, 2019: Novan's drug substance demonstrates inhibition of HPV-18 virus production
      • Jun 27, 2019: Verrica Pharmaceuticals enrolls first patient in Phase 2 trial of VP-102 for the treatment of external genital warts
      • Jun 26, 2019: Verrica Pharmaceuticals achieves positive topline results in phase 2 clinical study of VP-102 in [atients with common warts
      • Mar 18, 2019: Cytovation initiates clinical development programme with CyPep-1, a first-in-class lytic agent for tumor immunotherapy
      • Feb 19, 2019: Aclaris Therapeutics to present scientific posters at the 77th Annual Meeting of the American Academy of Dermatology
      • Nov 01, 2018: Novan Publication Supports Women's Health Business Unit Initiative and Nitric Oxide's Potential Against HPV-Associated Diseases
      • Sep 24, 2018: Aclaris Therapeutics Announces First Patient Dosed in Phase 3 Studies Evaluating A-101 45% in Patients with Common Warts
      • Jul 19, 2018: Cassiopea announces top line positive proof of concept phase II results for CB-06-02 immune modulator in treating genital warts
      • May 18, 2018: Rxi Pharmaceuticals Announces Positive Results from Phase 2 Trial with Samcyprone for the Treatment of Common Warts
      • Apr 04, 2018: Rxi Pharmaceuticals to Present on Samcyprone at the International Investigative Dermatology Conference
      • Mar 19, 2018: Aclaris Therapeutics Announces Positive Update on Phase 2 Results after a 3-month Follow-Up of A-101 45% Topical Solution for Potential Treatment of Common Warts
      • Jan 08, 2018: Aclaris Therapeutics A-101 45% Topical Solution Meets Primary and All Secondary Endpoints in Two Phase 2 Clinical Trials for Common Warts
      • Dec 07, 2017: Cassiopea Announces Completion of Recruitment of Phase II Proof of Concept Trial of CB-06-02 Trial in Genital Warts
      • Sep 06, 2017: Rxi Pharmaceuticals Announces Completion of Enrollment of Phase 2 Clinical Trial with Samcyprone for Cutaneous Warts
      • Jun 29, 2017: Aclaris Therapeutics Initiates Phase 2b Clinical Trials of A-101 for Topical Treatment of Common Warts
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top